Cargando…

Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer

BACKGROUND: This phase I dose escalation trial evaluated the feasibility of production, safety, maximum tolerated dose, and preliminary efficacy of autologous T cells sensitized with peptides encoding Wilms’ tumor protein 1 (WT1) administered alone or following lymphodepleting chemotherapy, in the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kyi, Chrisann, Doubrovina, Ekaterina, Zhou, Qin, Kravetz, Sara, Iasonos, Alexia, Aghajanian, Carol, Sabbatini, Paul, Spriggs, David, O'Reilly, Richard J, O’Cearbhaill, Roisin E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388302/ https://www.ncbi.nlm.nih.gov/pubmed/34433633 http://dx.doi.org/10.1136/jitc-2021-002752

Ejemplares similares

Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
por: Friedman, Claire F., et al.
Publicado: (2023)

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
por: O’Cearbhaill, Roisin E., et al.
Publicado: (2016)

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission
por: Manning-Geist, Beryl L., et al.
Publicado: (2023)

Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
por: Mun, Sung Soo, et al.
Publicado: (2023)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
por: Ferris, Robert L, et al.
Publicado: (2021)

Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy
por: Hasan, Aisha N., et al.
Publicado: (2022)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Portrait of an autologous cancer vaccine: Then and now
por: Berd, David
Publicado: (2023)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
por: Joerger, Markus, et al.
Publicado: (2023)

Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis
por: Gordhandas, Sushmita, et al.
Publicado: (2022)

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
por: Coveler, Andrew L, et al.
Publicado: (2023)

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
por: Boutros, Celine, et al.
Publicado: (2020)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
por: Bauer, Todd M, et al.
Publicado: (2023)

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
por: Koneru, Mythili, et al.
Publicado: (2015)

Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
por: Meng, Qingda, et al.
Publicado: (2021)

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
por: Rubinstein, Maria M., et al.
Publicado: (2023)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma
por: Restle, David, et al.
Publicado: (2023)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

Primary osteosarcoma of the uterus with cardiac and pulmonary metastases
por: Abraham, Cynthia, et al.
Publicado: (2014)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas
por: Crowley, Fionnuala, et al.
Publicado: (2022)

A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies
por: Iasonos, Alexia, et al.
Publicado: (2008)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
por: Homicsko, Krisztian, et al.
Publicado: (2023)

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
por: Naidoo, Jarushka, et al.
Publicado: (2021)

Elicitation of stem-like CD8(+) T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control
por: Manspeaker, Margaret P, et al.
Publicado: (2022)

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
por: Meneveau, Max O, et al.
Publicado: (2022)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
por: Boland, Julia L., et al.
Publicado: (2018)

Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects
por: Veeramachaneni, Ratna, et al.
Publicado: (2021)

CD163(+) cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer
por: Santegoets, Saskia J, et al.
Publicado: (2020)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
por: Godfrey, James, et al.
Publicado: (2023)

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
por: Barsoumian, Hampartsoum B, et al.
Publicado: (2020)

In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma
por: Mohsen, Mona O, et al.
Publicado: (2022)

Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study
por: Oseledchyk, Anton, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l6rgdans8gl0tme64r1mrpoh47